Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer

In a phase II study, 27 patients with metastatic breast cancer were treated with oral etoposide as second-line chemotherapy at a dose of 50 mg/m2/day for 21 days, which courses were repeated every 4 weeks. Twenty-one patients were evaluable for response, and twenty-five for toxicity. In two (10%) pa...

Ausführliche Beschreibung